Article · 26 Mar 2025
Conference abstractPublished 5 Dec 2019
Inzomelid is a CNS penetrant anti-inflammatory drug that blocks NLRP3 inflammasome activation targeted to prevent Synuclein Pathology and Dopaminergic Degeneration in Parkinsonand#8217;s disease
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Fibrillar synuclein is implicated in cell-to-cell transmission and neuronal degeneration in Lewy body diseases, but mechanisms linking synuclein pathology and dopaminergic neuronal loss to chronic microglial neuroinflammation have not been defined. We show that activation of the microglial NLRP3 inflammasome is a common pathway triggered by both fibrillar synuclein and dopaminergic degeneration in the absence of synuclein aggregates. Cleaved caspase-1 and the inflammasome adapter protein ASC are elevated in the substantia nigra and plasma of Parkinson’s patients, and in multiple preclinical Parkinson’s models including 6-hydroxydopamine, MitoPark, and the preformed fibril model of synuclein pathology.NLRP3 activation by fibrillar synuclein in microglia results in a delayed, but robust activation of the NLRP3 inflammasome, with substantial extracellular IL-1β and ASC release in the absence of pyroptosis. Nanomolar doses of the potent small molecule tool compound NLRP3 inhibitor, MCC950, or the clinical stage investigative drug Inzomelid, abolished fibrillar synuclein-mediated NLRP3 activation and extracellular ASC release. Further, Inzomelid is active in the central nervous system following oral dosing, and can mitigate inflammasome activation, motor deficits and nigrostriatal dopaminergic degeneration. Crucially, chronic NLRP3 inhibition effectively blocks fibrillar synuclein mediated motor deficits, dopamine loss and pathological synuclein spread in vivo. These findings suggest that the microglial NLRP3 inflammasome may be a sustained source of neuroinflammation that drives progressive neuropathology in Parkinson’s and highlight Inzomelid as a potential disease-modifying therapeutic target for Parkinson’s.
Keywords
Subjects
Neuroscience & NeurologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Neurology and Clinical Neuroscience.
Article · 30 Jan 2024
Are the pharmaceutical or alternative treatments most effective to treat Alzheimer's disease?
Article · 27 Jan 2024
Diplopia: A unique presenting symptom of neurobrucellosis – A case report
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Neurology and Clinical Neuroscience
- SubjectNeuroscience & Neurology
- BylineArticles whose byline prints “Matthew A Cooper”
